The Efficacy of Chinese Herbal Medicine as an Adjunctive Therapy for Advanced Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis
Open Access
- 28 February 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 8 (2) , e57604
Abstract
Many published studies reflect the growing application of complementary and alternative medicine, particularly Chinese herbal medicine (CHM) use in combination with conventional cancer therapy for advanced non-small cell lung cancer (NSCLC), but its efficacy remains largely unexplored. The purpose of this study is to evaluate the efficacy of CHM combined with conventional chemotherapy (CT) in the treatment of advanced NSCLC. Publications in 11 electronic databases were extensively searched, and 24 trials were included for analysis. A sum of 2,109 patients was enrolled in these studies, at which 1,064 patients participated in CT combined CHM and 1,039 in CT (six patients dropped out and were not reported the group enrolled). Compared to using CT alone, CHM combined with CT significantly increase one-year survival rate (RR = 1.36, 95% CI = 1.15–1.60, p = 0.0003). Besides, the combined therapy significantly increased immediate tumor response (RR = 1.36, 95% CI = 1.19–1.56, p<1.0E−5) and improved Karnofsky performance score (KPS) (RR = 2.90, 95% CI = 1.62–5.18, p = 0.0003). Combined therapy remarkably reduced the nausea and vomiting at toxicity grade of III–IV (RR = 0.24, 95% CI = 0.12–0.50, p = 0.0001) and prevented the decline of hemoglobin and platelet in patients under CT at toxicity grade of I–IV (RR = 0.64, 95% CI = 0.51–0.80, p<0.0001). Moreover, the herbs that are frequently used in NSCLC patients were identified. This systematic review suggests that CHM as an adjuvant therapy can reduce CT toxicity, prolong survival rate, enhance immediate tumor response, and improve KPS in advanced NSCLC patients. However, due to the lack of large-scale randomized clinical trials in the included studies, further larger scale trials are needed.Keywords
This publication has 45 references indexed in Scilit:
- Astragalus membranaceus Ameliorates Reproductive Toxicity Induced by Cyclophosphamide in Male MicePhytotherapy Research, 2012
- Guidelines for randomised controlled trials investigating Chinese herbal medicineJournal of Ethnopharmacology, 2012
- Complementary and alternative medicine use in oncology: A questionnaire survey of patients and health care professionalsBMC Cancer, 2011
- Effects of chemotherapy combined with Chinese herbal medicine Kangliu Zengxiao Decoction on tumor markers of patients with advanced non-small-cell lung cancer: a randomized, controlled trialJournal of Chinese Integrative Medicine, 2011
- Astragalus-containing Chinese herbal combinations for advanced non-small-cell lung cancer: a meta-analysis of 65 clinical trials enrolling 4751 patientsLung Cancer: Targets and Therapy, 2010
- Long-Term Results of the International Adjuvant Lung Cancer Trial Evaluating Adjuvant Cisplatin-Based Chemotherapy in Resected Lung CancerJournal of Clinical Oncology, 2010
- Haishengsu as an adjunct therapy to conventional chemotherapy in patients with non-small cell lung cancer: A pilot randomized and placebo-controlled clinical trialComplementary Therapies in Medicine, 2009
- Herbal Medicine in the United States: Review of Efficacy, Safety, and RegulationJournal of General Internal Medicine, 2008
- Effects of Radix Adenophorae and Cyclosporine A on an OVA‐Induced Murine Model of Asthma by Suppressing to T Cells Activity, Eosinophilia, and Bronchial HyperresponsivenessMediators of Inflammation, 2008
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996